161 related articles for article (PubMed ID: 38092979)
1. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab.
Laheij AMGA; van de Donk NWCJ
Support Care Cancer; 2023 Dec; 32(1):20. PubMed ID: 38092979
[TBL] [Abstract][Full Text] [Related]
2. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
[TBL] [Abstract][Full Text] [Related]
3. Dermatological toxicities induced by T-cell-redirecting G protein-coupled receptor family C class 5 member D bispecific antibody talquetamab.
Lery M; Perrot A; Ortiz-Brugués A; Vigarios E; Anghel D; Bories P; Sibaud V
J Am Acad Dermatol; 2024 Feb; 90(2):376-377. PubMed ID: 37742842
[No Abstract] [Full Text] [Related]
4. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.
Verkleij CPM; Broekmans MEC; van Duin M; Frerichs KA; Kuiper R; de Jonge AV; Kaiser M; Morgan G; Axel A; Boominathan R; Sendecki J; Wong A; Verona RI; Sonneveld P; Zweegman S; Adams HC; Mutis T; van de Donk NWCJ
Blood Adv; 2021 Apr; 5(8):2196-2215. PubMed ID: 33890981
[TBL] [Abstract][Full Text] [Related]
5. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
6. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
7. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma.
Chari A; Askari E; Caers J; Costa LJ; Hilder BW; Krishnan A; Mateos MV; Minnema MC; Oriol A; Pillarisetti K; van de Donk NWCJ; Rodríguez-Otero P
Future Oncol; 2023 Sep; 19(27):1823-1840. PubMed ID: 37492991
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
9. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
10. Talquetamab: First Approval.
Keam SJ
Drugs; 2023 Oct; 83(15):1439-1445. PubMed ID: 37792138
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy.
Sapir E; Tao Y; Feng F; Samuels S; El Naqa I; Murdoch-Kinch CA; Feng M; Schipper M; Eisbruch A
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):354-361. PubMed ID: 27473816
[TBL] [Abstract][Full Text] [Related]
12. MonumenTAL Results for Talquetamab in Myeloma.
Cancer Discov; 2023 Feb; 13(2):250-251. PubMed ID: 36508587
[TBL] [Abstract][Full Text] [Related]
13. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
14. Talquetamab in multiple myeloma.
Liu L; Krishnan A
Haematologica; 2024 Mar; 109(3):718-724. PubMed ID: 37855056
[TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Einsele H; Moreau P; Bahlis N; Bhutani M; Vincent L; Karlin L; Perrot A; Goldschmidt H; van de Donk NWCJ; Ocio EM; Martinez-Lopez J; Rodríguez-Otero P; Dytfeld D; Diels J; Strulev V; Haddad I; Renaud T; Ammann E; Cabrieto J; Perualila N; Gan R; Zhang Y; Parekh T; Albrecht C; Weisel K; Mateos MV
Adv Ther; 2024 Apr; 41(4):1576-1593. PubMed ID: 38402374
[TBL] [Abstract][Full Text] [Related]
16. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
Pillarisetti K; Edavettal S; Mendonça M; Li Y; Tornetta M; Babich A; Majewski N; Husovsky M; Reeves D; Walsh E; Chin D; Luistro L; Joseph J; Chu G; Packman K; Shetty S; Elsayed Y; Attar R; Gaudet F
Blood; 2020 Apr; 135(15):1232-1243. PubMed ID: 32040549
[TBL] [Abstract][Full Text] [Related]
17. Association of xerostomia and taste alterations of patients receiving antineoplastic chemotherapy: A cause for nutritional concern.
Silva IMV; Donaduzzi LC; Perini CC; Couto SAB; Werneck RI; de Araújo MR; Kurahashi M; Johann ACBR; Azevedo-Alanis LR; Vieira AR; Couto-Souza PH
Clin Nutr ESPEN; 2021 Jun; 43():532-535. PubMed ID: 34024566
[TBL] [Abstract][Full Text] [Related]
18. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.
Lipe BC; Renaud T
J Oncol Pharm Pract; 2023 Jun; 29(4):1006-1010. PubMed ID: 36464766
[TBL] [Abstract][Full Text] [Related]
19. Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents.
Del Giudice ML; Galimberti S; Buda G
Cancer Immunol Immunother; 2023 Dec; 72(12):3931-3937. PubMed ID: 37924369
[TBL] [Abstract][Full Text] [Related]
20. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
